Answers are grounded in this paper and cite their sources.
MAD2L1 (Mitotic Arrest Deficient 2 Like 1) is the gene encoding the mitotic checkpoint protein MAD2, a key component of the mitotic spindle assembly checkpoint, and plays an essential role in maintaining chromosomal stability during cell division. Aberrant MAD2 expression has been linked to tumorigenesis and cancer progression; however, its prognostic significance in human malignancies is not yet fully defined. This study aimed to systematically and quantitatively evaluate, through a meta-analysis, the clinicopathological and prognostic relevance of MAD2L1 expression in cancer. A systematic literature review was conducted using PubMed, Web of Science, and Scopus databases up to December 2025 to identify studies evaluating MAD2L1 expression in human cancers. The risk of bias of the included prognostic studies was assessed using the Quality in Prognosis Studies (QUIPS) tool. The meta-analysis was performed using overall survival (OS) and was analyzed quantitatively; studies reporting hazard ratios (HRs) and their confidence intervals (CIs). The protocol was registered with PROSPERO CRD420261330469. This study included 61 articles in the systematic review, encompassing 22 cancer types and a total of 5,734 tissue samples. In the quantitative synthesis, four studies reporting overall survival (breast, cholangiocarcinoma, lung, and endometrial cancer; 659 patients) were pooled. High MAD2L1 expression was associated with increased risk, with a pooled hazard ratio of 2.75 (95% CI 1.08–7.05; p = 0.042) under the random-effects model with Hartung-Knapp adjustment, and moderate heterogeneity (I² = 47.4%). The prediction interval (0.80–9.51) included the null value, and a sensitivity analysis excluding one study whose estimate was not identifiable gave a pooled hazard ratio of 2.43 (95% CI 1.27–4.67). The pooled primary estimate combines three studies reporting overall survival with one reporting disease-specific survival; a sensitivity analysis restricted to overall-survival studies gave a comparable common-effect estimate (2.65; 95% CI 1.73–4.05) with reduced precision. The quantitative synthesis should therefore be regarded as exploratory. Pan-cancer bioinformatic analysis revealed significantly increased MAD2L1 expression in many tumor types compared with normal tissues, supporting its potential role in tumorigenesis. The data from the systematic review, meta-analysis, and bioinformatics analysis provide evidence that MAD2L1 overexpression is associated with a tumor phenotype and an unfavorable prognosis in various cancer types, supporting its potential use as a prognostic biomarker in cancer.
No takes yet. Share an insight, caveat, or question.
Galindo-Alcazar et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: